- Home
- SBH vs EWTX Comparison
SBH vs EWTX Comparison
Compare SBH & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBH
- EWTX
- Stock Information
- Founded
- SBH 1964
- EWTX 2017
- Country
- SBH United States
- EWTX United States
- Employees
- SBH N/A
- EWTX N/A
- Industry
- SBH Other Specialty Stores
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- SBH Consumer Discretionary
- EWTX Health Care
- Exchange
- SBH Nasdaq
- EWTX Nasdaq
- Market Cap
- SBH 1.5B
- EWTX 1.6B
- IPO Year
- SBH 2006
- EWTX 2021
- Fundamental
- Price
- SBH $14.04
- EWTX $17.24
- Analyst Decision
- SBH Buy
- EWTX Buy
- Analyst Count
- SBH 6
- EWTX 10
- Target Price
- SBH $14.00
- EWTX $37.90
- AVG Volume (30 Days)
- SBH 1.9M
- EWTX 842.1K
- Earning Date
- SBH 11-13-2025
- EWTX 11-06-2025
- Dividend Yield
- SBH N/A
- EWTX N/A
- EPS Growth
- SBH 35.04
- EWTX N/A
- EPS
- SBH 1.85
- EWTX N/A
- Revenue
- SBH $3,689,376,000.00
- EWTX N/A
- Revenue This Year
- SBH $0.16
- EWTX N/A
- Revenue Next Year
- SBH $1.32
- EWTX N/A
- P/E Ratio
- SBH $7.46
- EWTX N/A
- Revenue Growth
- SBH N/A
- EWTX N/A
- 52 Week Low
- SBH $7.54
- EWTX $10.60
- 52 Week High
- SBH $16.82
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- SBH 41.64
- EWTX 58.23
- Support Level
- SBH $14.72
- EWTX $16.82
- Resistance Level
- SBH $14.68
- EWTX $18.26
- Average True Range (ATR)
- SBH 0.55
- EWTX 0.93
- MACD
- SBH -0.14
- EWTX 0.10
- Stochastic Oscillator
- SBH 16.03
- EWTX 63.95
About SBH Sally Beauty Holdings Inc. (Name to be changed from Sally Holdings Inc.)
Sally Beauty Holdings Inc is a professional beauty-products retailer based in the United States. Sally Beauty operates throughout the United States, Puerto Rico, the United Kingdom, Belgium, Canada, Chile, Mexico, Peru, France, Ireland, Spain, Germany, and the Netherlands. The company operates through two business segments: Sally Beauty Supply and Beauty Systems Group. Product offerings include hair color and care, hair dryers and hair-styling appliances, nail care, skin care, and others.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.